Summary This latest Pharmaceutical and Healthcare disease pipeline guide Rotavirus Infections - Drugs In Development, 2022, provides an overview of the Rotavirus Infections (Infectious Disease) pipeline landscape.
New York, Sept. 26, 2022 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Rotavirus Infections Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update" - https://www.reportlinker.com/p06319563/?utm_source=GNW Rotavirus is a virus that infects the bowels. Rotavirus is the most common cause of severe diarrhea among infants and children. Transmission of rotavirus most often occurs through fecal-oral contact. Usually, this occurs from poor hand washing or from ingestion of contaminated food or water. The virus may also be transmitted through the respiratory tract or by other body fluids, but these routes are less common. The virus may live on inanimate surfaces, such as doorknobs, toys, and hard surfaces. Symptoms may include severe diarrhea, vomiting, fever, and dehydration. Report Highlights Pharmaceutical and Healthcare latest pipeline guide Rotavirus Infections - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Rotavirus Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Rotavirus Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Rotavirus Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 3, 1, 3, 1, 4 and 5 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages comprises 2, 1, 1, 1, 1 and 1 molecules, respectively. Rotavirus Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Rotavirus Infections (Infectious Disease). - The pipeline guide reviews pipeline therapeutics for Rotavirus Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Rotavirus Infections (Infectious Disease) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Rotavirus Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Rotavirus Infections (Infectious Disease) Reasons to Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Rotavirus Infections (Infectious Disease). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Rotavirus Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline. Read the full report: https://www.reportlinker.com/p06319563/?utm_source=GNW About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place. __________________________
Two marathon runners tell BBC Newsbeat about overcoming the odds to compete in the London Marathon.
A new study highlights risk factors driving increasing incidence of early-onset cancers. Researchers hypothesize why cancer is on the rise among young people.
Shares of Biogen (NASDAQ: BIIB) shot up as much as 37.1% this week, according to data from S&P Global Market Intelligence. The large-cap drugmaker with a market cap of $39 billion announced that its new Alzheimer's drug it developed in a partnership with Eisai showed tremendous promise in a clinical trial. As of 12:42 p.m. ET on Friday, shares of Biogen were up 35.5% this week.
New CDC data yields insight into relative health of various states
Biohaven Pharmaceuticals (BHVN) suffers a setback as verdiperstat fails to meet the primary and secondary endpoints in an ALS study.
"My name is Kathy Najimy and I've had an abortion," the "Hocus Pocus" star says in a powerful new PSA.
Leading drug company Eli Lilly broke above its buy point of 335.43 from a flat base on Wednesday. Trading surged to almost twice the usual volume as investors bought shares of the leading biopharmaceutical company. Shares also surged in sympathy after Biogen's successful trial for a drug to treat Alzheimer's, announced on Thursday.
If approved, Sarepta's (SRPT) SRP-9001 will be the first gene therapy for DMD indication in the United States. The company seeks approval for gene therapy under the accelerated pathway.
In the past two years, biotech companies Moderna (NASDAQ: MRNA) and Novavax (NASDAQ: NVAX) rose to fame thanks to their successful attempts to develop vaccines for COVID-19 and help us end the outbreak. The pandemic isn't over yet, but Moderna and Novavax have given up substantial chunks of their value in the past year. Where does that leave Moderna and Novavax?
The success of Biogen (BIIB)-Eisai's AD candidate in a big phase III study makes investors optimistic about the prospects of other AD candidates as well.
America’s health care system is not enough, even for those able to obtain health insurance through their employer.
If you're enrolled in Medicare, you should know that open enrollment will soon kick off. Each year, seniors on Medicare can make changes to their existing coverage, from Oct. 15 all the way through Dec. 7. Medicare Advantage and Part D drug plans can change from year to year.
A neurosurgeon on TikTok has revealed five things you should never do to have a healthy brain.Source: SWNS
'Gestational diabetes is not your fault,' says the reality star, 37.
Bill Gates told an audience that his foundation targets infectious diseases such as malaria, polio, HIV, and Covid, which hit poor nations hard. Gene sequencing is a starting point for many of these battles.
New mom jealousy is real — I had it after my first baby was born. I would feel anxious if other people were holding my newborn too long or if he smiled at other people. I was later diagnosed with postpartum anxiety, and it all made so much sense. Those feelings I had may have […]
In a year when prices are going up, Medicare Part B premiums are actually going down. A single drug is a major factor.